Showing results (51-60 of 133) with videos related to

Sort By:
Pageof 14
American Journal of Hypertension|June 8, 2014
Cotreatment with interleukin 4 and interleukin 10 modulates immune cells and prevents hypertension in pregnant micePiyali Chatterjee, Valorie L Chiasson, Geetha Seerangan, et al.
The American Journal of Pathology|October 26, 2010
Down-regulation of the oncogene cyclin D1 increases migratory capacity in breast cancer and is linked to unfavorable prognostic featuresSophie Lehn, Nicholas P Tobin, Pontus Berglund, et al.
Molecular Biology of the Cell|January 28, 2026
Lipid Droplets are rigid and physically suppress phagocytosis, unless cell compression or stretching activates actomyosinMichael P Tobin, Irena L Ivanovska, Steven H Phan, et al.
Journal of Leukocyte Biology|October 14, 2023
Dysfunctional states of unconventional T-cell subsets in cancerElizabeth N Katsnelson, Andrea Spengler, Joanne Domenico, et al.
Journal of Hypertension|April 5, 2013
Interleukin-4 deficiency induces mild preeclampsia in micePiyali Chatterjee, Shelley E Kopriva, Valorie L Chiasson, et al.
The Journal of Pathology. Clinical Research|February 1, 2017
High expression of stromal PDGFRβ is associated with reduced benefit of tamoxifen in breast cancerJanna Paulsson, Lisa Rydén, Carina Strell, et al.
Journal of Leukocyte Biology|November 17, 2025
Human M-MDSCs impair neutrophil migration in the infectious microenvironmentHannah K Weppner, Maya A Singh, Elizabeth N Katsnelson, et al.
Metabolites|January 27, 2026
Profiling Serum Oxylipin Metabolites Across Melanoma Subtypes and Immunotherapy RespondersAlexander C Goodman, Kylie M Michel, Morgan L MacBeth, et al.
Molecular Oncology|March 3, 2020
Programmed death-ligand 1 gene expression is a prognostic marker in early breast cancer and provides additional prognostic value to 21-gene and 70-gene signatures in estrogen receptor-positive diseaseIoannis Zerdes, Emmanouil G Sifakis, Alexios Matikas, et al.
American Journal of Physiology. Renal Physiology|August 22, 2019
Antagonism of major histocompatibility complex class II invariant chain peptide during chronic lipopolysaccharide treatment rescues autoregulatory behaviorJustin P Van Beusecum, Shali Zhang, Estevan Beltran, et al.
Pageof 14